PARIS – Gleamer SAS has secured $8.75 million in series A financing for its CE-marked artificial intelligence (AI) application that automatically detects all types of fracture in radiography. “This funding will allow us to move forward with launching Boneview around the world,” Christian Allouche, CEO and co-founder of Gleamer, told BioWorld.
Med-tech firms raising money in public or private financings, including: Anpac Bio-Medical Science, Sophia Genetics, Tissium, Varex Imaging, Well Health Technologies, Wise.
With a just-completed $100 million common stock financing, Flame Biosciences Inc. plans to target the inflammasome, a protein complex that sets off innate immune responses by activating the cytokines IL-1beta and IL-18.
HONG KONG – Shanghai-based Bioshin Ltd., the Asia-Pacific arm of New Haven, Conn.-based Biohaven Pharmaceutical Holding Co. Ltd., has added $60 million to its war chest via a series A investment.
PERTH, Australia – Starpharma Holdings Ltd. completed a AU$45 million (US$32 million) placement to domestic and international investors that will see it advance its COVID-19 antiviral nasal spray. The treatment is based on the company’s antiviral dendrimer, SPL-7013, which inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins.
PERTH, Australia – Brandon Capital announced the launch of Ena Respiratory Pty Ltd., which has developed a nasal treatment to boost the natural immune system to fight common colds and flu and has proved successful in reducing COVID-19 viral replication.
RSS
